Heron Therapeutics Inc (HRTX) Receives Consensus Rating of “Buy” from Analysts

Shares of Heron Therapeutics Inc (NASDAQ:HRTX) have received a consensus rating of “Buy” from the thirteen research firms that are currently covering the firm, Marketbeat reports. Three research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. The average twelve-month price target among brokers that have issued a report on the stock in the last year is $31.13.

Several brokerages have issued reports on HRTX. ValuEngine raised shares of Heron Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, February 2nd. BidaskClub cut shares of Heron Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, January 31st. Zacks Investment Research raised shares of Heron Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, November 8th. Oppenheimer reissued a “buy” rating and issued a $27.00 price objective on shares of Heron Therapeutics in a research note on Friday, November 10th. Finally, Cantor Fitzgerald set a $31.00 price objective on shares of Heron Therapeutics and gave the company a “buy” rating in a research note on Friday, January 5th.

In other news, VP Kimberly Manhard sold 7,584 shares of the company’s stock in a transaction on Wednesday, January 10th. The shares were sold at an average price of $20.00, for a total transaction of $151,680.00. Following the transaction, the vice president now directly owns 7,584 shares of the company’s stock, valued at approximately $151,680. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Corporate insiders own 19.93% of the company’s stock.

Several large investors have recently bought and sold shares of HRTX. Pinnacle Associates Ltd. acquired a new position in shares of Heron Therapeutics during the 4th quarter worth $201,000. Trexquant Investment LP acquired a new position in shares of Heron Therapeutics during the 3rd quarter worth $206,000. Jane Street Group LLC acquired a new position in shares of Heron Therapeutics during the 3rd quarter worth $223,000. UBS Asset Management Americas Inc. acquired a new position in shares of Heron Therapeutics during the 4th quarter worth $230,000. Finally, HighTower Advisors LLC grew its stake in shares of Heron Therapeutics by 11.4% during the 2nd quarter. HighTower Advisors LLC now owns 16,584 shares of the biotechnology company’s stock worth $231,000 after purchasing an additional 1,700 shares during the period. 98.71% of the stock is currently owned by institutional investors and hedge funds.

Shares of Heron Therapeutics (NASDAQ:HRTX) traded up $0.90 on Tuesday, reaching $22.40. 602,084 shares of the company’s stock traded hands, compared to its average volume of 1,018,733. The company has a quick ratio of 2.02, a current ratio of 2.12 and a debt-to-equity ratio of 0.62. The firm has a market cap of $1,170.00, a PE ratio of -5.67 and a beta of 1.87. Heron Therapeutics has a 12 month low of $12.70 and a 12 month high of $24.80.

WARNING: This piece was originally published by American Banking News and is owned by of American Banking News. If you are accessing this piece on another site, it was illegally stolen and republished in violation of U.S. and international trademark and copyright legislation. The correct version of this piece can be read at https://www.americanbankingnews.com/2018/02/13/heron-therapeutics-inc-hrtx-receives-consensus-rating-of-buy-from-analysts.html.

About Heron Therapeutics

Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.

Analyst Recommendations for Heron Therapeutics (NASDAQ:HRTX)

Receive News & Ratings for Heron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply